Federation des caisses Desjardins du Quebec’s Esperion Therapeutics ESPR Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200	Closed	-$4.23K	–	2576
2021 Q2	$4.23K	Hold	200	–	–	﹤0.01%	2290
2021 Q1	$5.61K	Hold	200	–	–	﹤0.01%	2166
2020 Q4	$5.2K	Hold	200	–	–	﹤0.01%	2056
2020 Q3	$7.43K	Hold	200	–	–	﹤0.01%	1758
2020 Q2	$10.3K	Hold	200	–	–	﹤0.01%	1633
2020 Q1	$6.31K	Hold	200	–	–	﹤0.01%	1770
2019 Q4	$11.9K	Hold	200	–	–	﹤0.01%	1853
2019 Q3	$7.33K	Hold	200	–	–	﹤0.01%	1885
2019 Q2	$9.3K	Hold	200	–	–	﹤0.01%	1867
2019 Q1	$8.03K	Hold	200	–	–	﹤0.01%	1714
2018 Q4	$9.2K	Sell	200 -150	-43%	-$7.23K	﹤0.01%	1640
2018 Q3	$15.5K	Sell	350 -100	-22%	-$4.59K	﹤0.01%	1614
2018 Q2	$17.6K	Sell	450 -275	-38%	-$13.9K	﹤0.01%	1600
2018 Q1	$52.4K	Buy	+725	New	+$53.2K	﹤0.01%	1315

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ESPR Position: Q3 2021 in Review

Federation des caisses Desjardins du Quebec sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 200 shares — an estimated $4.23K sold.

Federation des caisses Desjardins du Quebec first reported a position in ESPR in Q1 2018 and held it in 14 quarters. The position peaked at $52.4K in Q1 2018. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

Federation des caisses Desjardins du Quebec reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 200 Esperion Therapeutics shares in Q3 2021, an estimated $4.23K.
Federation des caisses Desjardins du Quebec first reported a position in Esperion Therapeutics in Q1 2018 and held it in 14 quarters.
Federation des caisses Desjardins du Quebec's Esperion Therapeutics position peaked at $52.4K in Q1 2018.
139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2021, filed 30 Aug 2024.